Search results
Showing 4261 to 4275 of 8925 results
Selective internal radiation therapy for primary hepatocellular carcinoma (HTG314)
Evidence-based recommendations on selective internal radiation therapy (SIRT) for primary hepatocellular carcinoma. This involves infusion of microspheres loaded with yttrium-90, which aims to deliver radiation directly into the tumour, minimising the risk of radiation damage to healthy surrounding tissues.
View recommendations for HTG314Show all sections
Sections for HTG314
Evidence-based recommendations on the ReCell Spray-On Skin system for treating skin loss, scarring and depigmentation after burn injury.
E‑vita open plus for treating complex aneurysms and dissections of the thoracic aorta (HTG326)
Evidence-based recommendations on the E-vita open plus for treating complex aneurysms and dissections of the thoracic aorta.
Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care (HTG607)
Evidence-based recommendations on Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care.
Ultrasound‑enhanced, catheter‑directed thrombolysis for deep vein thrombosis (HTG375)
Evidence-based recommendations on ultrasound enhanced catheter-directed thrombolysis for deep vein thrombosis. This involves using ultrasound waves and a drug to break up the clot.
Evidence-based recommendations on single incision laparoscopic cholecystectomy. This involves removing the gallbladder through a small cut, most often below the bellly button.
Minimally invasive video‑assisted parathyroidectomy (HTG350)
Evidence-based recommendations on minimally invasive video-assisted parathyroidectomy. This involves inserting surgical instruments through a small cut (keyhole surgery) to find and remove any abnormal glands.
Ultrasound‑enhanced, catheter‑directed thrombolysis for pulmonary embolism (HTG376)
Evidence-based recommendations on ultrasound enhanced catheter-directed thrombolysis for pulmonary embolism. This involves using ultrasound waves and a drug to break up the clot.
A new model for evaluating and purchasing antimicrobials in the UK
Overview of NICE and NHS England’s pioneering subscription-style purchasing model for antimicrobials: its pilot with ceftazidime-avibactam and cefiderocol in 2022, expansion in 2024, supporting health technology assessments, downloadable guidance and procurement tools.
This indicator covers the percentage of patients with a new diagnosis of hypertension in the preceding 1 April to 31 March who have a record of a 12-lead ECG performed in the 3 months before or after the date of entry to the hypertension register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM77
Woundchek Protease Status for assessing elevated protease status in chronic wounds (MIB83)
NICE has developed a medtech innovation briefing (MIB) on the Woundchek Protease Status for assessing elevated protease status in chronic wounds .
NICE has developed a medtech innovation briefing (MIB) on the needle-free arterial non-injectable connector .
NICE has developed a medtech innovation briefing (MIB) on OCS Heart system for heart transplant .
NICE has developed a medtech innovation briefing (MIB) on CytoSorb therapy for sepsis .
Sternal Talon for sternal closure in cardiothoracic surgery (MIB88)
NICE has developed a medtech innovation briefing (MIB) on the Sternal Talon for sternal closure in cardiothoracic surgery .